392 related articles for article (PubMed ID: 25601201)
21. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
22. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
23. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
24. Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?
Radomski L; Gani J; Trottier G; Finelli A
Can J Urol; 2012 Jun; 19(3):6287-92. PubMed ID: 22704315
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Pathological Outcomes for Men with Low Risk Prostate Cancer from Diverse Practice Settings: Similar Results from Immediate Prostatectomy or Initial Surveillance with Delayed Prostatectomy.
Auffenberg GB; Linsell S; Dhir A; Myers SN; Rosenberg B; Miller DC;
J Urol; 2016 Nov; 196(5):1415-1421. PubMed ID: 27256204
[TBL] [Abstract][Full Text] [Related]
26. Active surveillance for prostate cancer: an Australian experience.
Ischia JJ; Pang CY; Tay YK; Suen CF; Aw HC; Frydenberg M
BJU Int; 2012 Apr; 109 Suppl 3():40-3. PubMed ID: 22458492
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia.
Ruseckaite R; Sampurno F; Millar J; Frydenberg M; Evans S
BMC Urol; 2016 Sep; 16(1):54. PubMed ID: 27589955
[TBL] [Abstract][Full Text] [Related]
28. Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.
Preston MA; Feldman AS; Coen JJ; McDougal WS; Smith MR; Paly JJ; Carrasquillo R; Wu CL; Dahl DM; Barrisford GW; Blute ML; Zietman AI
Urol Oncol; 2015 Sep; 33(9):383.e9-16. PubMed ID: 26059076
[TBL] [Abstract][Full Text] [Related]
29. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
[TBL] [Abstract][Full Text] [Related]
30. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
31. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer in Victoria in 1993: patterns of reported management.
Frydenberg M; Giles GG; Mameghan H; Thursfield VJ; Millar J; Wheelahan JB; Bolton DM; Syme RR
Med J Aust; 2000 Mar; 172(6):270-4. PubMed ID: 10860092
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
Lao C; Edlin R; Rouse P; Brown C; Holmes M; Gilling P; Lawrenson R
BMC Cancer; 2017 Aug; 17(1):529. PubMed ID: 28789623
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
35. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
Gaffney C; Golan R; Cantu MD; Scognamiglio T; McCarthy H; Mosquera JM; McClure TD; Barbieri CE; Robinson BD; Khani F
J Urol; 2019 Jul; 202(1):96-101. PubMed ID: 30933552
[TBL] [Abstract][Full Text] [Related]
36. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
37. Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry.
Bolton DM; Papa N; Ta AD; Millar J; Davidson AJ; Pedersen J; Syme R; Patel MI; Giles GG
BJU Int; 2015 Oct; 116 Suppl 3():66-72. PubMed ID: 26176738
[TBL] [Abstract][Full Text] [Related]
38. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
39. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
[TBL] [Abstract][Full Text] [Related]
40. Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the Prostate Cancer Registry.
Daniels CP; Millar JL; Spelman T; Sengupta S; Evans SM
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):247-54. PubMed ID: 26548940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]